Ranbaxy recalls generic Lipitor in US, stock tumbles
- Parliament LIVE: Jaitley has promised concrete proposals on GST, says Chidambaram
- Kashmir violence -- Omar Abdullah interview: 'It has been building up to this'
- Baton Rouge shootings: Three officers killed, suspect dead
- Grading writers, artistes is new brainwave of Culture Ministry
- Reforms not because of Cong, in spite of it... credit goes to Rao-Singh: Arun Jaitley
RANBAXY Labs Ltd, the country's top drugmaker by sales, said it is recalling its cholesterol-lowering drug Atorvastatin calcium in the United States, a generic version of Lipitor, as some batches may contain very small glass particles. The drug largely drove the company's sales in the first half of the year.
The latest recall for Ranbaxy, already on alert under a US Food and Drug Administration scrutiny for past slippages, is being conducted at the retail level. This will temporarily disrupt supplies of Atorvastatin in the US while it conducts an investigation, the company said in a statement. Shares of Ranbaxy, controlled by Japan's Daiichi Sankyo, closed down 3.27 per cent at Rs 496 following the announcement.
"Ranbaxy...is conducting a voluntary recall for Atorvastatin calcium tablets, in connection with its 10 mg 20 mg and 40 mg dosage strengths...only with respect to certain select lot numbers...The recall is being conducted at the retail level for such select batches that may contain a foreign substance (small glass particles approximately less than 1 mm in size)," the statement said.
The direct impact of the recall, without factoring in two weeks of disruption in supplies, is being pegged by analysts at close to $5 million. This disruption may also dent the company's Lipitor market share of over 45 per cent in the US.
- Congress opposition to GST does no credit to a party that opened up the economy 25 years ago
- Kashmir poses not just moral but also existential questions involving statecraft
- New FDI policy in food products is unlikely to be a game-changer by itself
- Swathi murder case in Chennai must trigger a move to enact strong witness protection laws
- A new government in Nepal does not hold out any promise of greater stability
- Kashmir is more than land, it is people